CytomX Net Income vs Free Cash Flow Analysis

CTMX Stock  USD 1.15  0.04  3.60%   
CytomX Therapeutics financial indicator trend analysis is way more than just evaluating CytomX Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytomX Therapeutics is a good investment. Please check the relationship between CytomX Therapeutics Net Income and its Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Net Income vs Free Cash Flow

Net Income vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytomX Therapeutics Net Income account and Free Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between CytomX Therapeutics' Net Income and Free Cash Flow is 0.48. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of CytomX Therapeutics, assuming nothing else is changed. The correlation between historical values of CytomX Therapeutics' Net Income and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of CytomX Therapeutics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Net Income i.e., CytomX Therapeutics' Net Income and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.48
Relationship DirectionPositive 
Relationship StrengthWeak

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in CytomX Therapeutics financial statement analysis. It represents the amount of money remaining after all of CytomX Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
Most indicators from CytomX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.Tax Provision is likely to rise to about 3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 28.8 M in 2024.
 2021 2022 2023 2024 (projected)
Gross Profit69.6M53.2M101.2M54.2M
Total Revenue69.6M53.2M101.2M54.2M

CytomX Therapeutics fundamental ratios Correlations

0.880.880.70.650.90.60.56-0.84-0.60.670.850.64-0.160.381.00.19-0.11-0.110.330.90.86-0.880.810.440.89
0.880.690.520.780.730.490.38-0.73-0.440.870.730.560.00.410.870.15-0.01-0.010.070.850.63-0.930.730.330.65
0.880.690.860.410.820.80.71-0.77-0.790.430.810.81-0.30.260.850.31-0.16-0.160.650.730.75-0.810.760.70.89
0.70.520.860.090.810.740.9-0.52-0.940.210.570.72-0.360.250.640.5-0.32-0.320.840.690.59-0.750.730.820.85
0.650.780.410.090.360.15-0.12-0.630.050.780.590.210.050.260.7-0.330.280.28-0.290.610.32-0.60.38-0.10.24
0.90.730.820.810.360.550.69-0.7-0.690.490.710.57-0.070.310.890.35-0.22-0.220.510.910.88-0.810.760.480.95
0.60.490.80.740.150.550.64-0.49-0.740.150.570.99-0.360.510.530.21-0.14-0.140.620.40.52-0.60.740.830.68
0.560.380.710.9-0.120.690.64-0.22-0.980.080.280.62-0.260.180.50.49-0.68-0.680.790.590.48-0.670.620.890.74
-0.84-0.73-0.77-0.52-0.63-0.7-0.49-0.220.32-0.64-1.0-0.530.32-0.35-0.83-0.28-0.38-0.38-0.23-0.63-0.80.63-0.69-0.17-0.76
-0.6-0.44-0.79-0.940.05-0.69-0.74-0.980.32-0.13-0.38-0.730.32-0.19-0.54-0.50.570.57-0.82-0.59-0.490.72-0.64-0.94-0.76
0.670.870.430.210.780.490.150.08-0.64-0.130.610.240.240.180.690.050.120.12-0.180.630.45-0.730.450.010.39
0.850.730.810.570.590.710.570.28-1.0-0.380.610.61-0.350.390.830.290.350.350.290.630.81-0.650.730.250.79
0.640.560.810.720.210.570.990.62-0.53-0.730.240.61-0.310.540.580.18-0.13-0.130.580.440.55-0.650.770.810.7
-0.160.0-0.3-0.360.05-0.07-0.36-0.260.320.320.24-0.35-0.31-0.39-0.11-0.4-0.21-0.21-0.35-0.03-0.150.1-0.33-0.36-0.27
0.380.410.260.250.260.310.510.18-0.35-0.190.180.390.54-0.390.37-0.10.110.110.070.250.36-0.310.740.250.35
1.00.870.850.640.70.890.530.5-0.83-0.540.690.830.58-0.110.370.12-0.11-0.110.270.910.85-0.860.780.380.85
0.190.150.310.5-0.330.350.210.49-0.28-0.50.050.290.18-0.4-0.10.12-0.03-0.030.420.20.36-0.290.230.350.47
-0.11-0.01-0.16-0.320.28-0.22-0.14-0.68-0.380.570.120.35-0.13-0.210.11-0.11-0.031.0-0.34-0.24-0.050.26-0.12-0.55-0.18
-0.11-0.01-0.16-0.320.28-0.22-0.14-0.68-0.380.570.120.35-0.13-0.210.11-0.11-0.031.0-0.34-0.24-0.050.26-0.12-0.55-0.18
0.330.070.650.84-0.290.510.620.79-0.23-0.82-0.180.290.58-0.350.070.270.42-0.34-0.340.290.34-0.360.410.770.61
0.90.850.730.690.610.910.40.59-0.63-0.590.630.630.44-0.030.250.910.2-0.24-0.240.290.71-0.890.690.390.78
0.860.630.750.590.320.880.520.48-0.8-0.490.450.810.55-0.150.360.850.36-0.05-0.050.340.71-0.610.730.30.92
-0.88-0.93-0.81-0.75-0.6-0.81-0.6-0.670.630.72-0.73-0.65-0.650.1-0.31-0.86-0.290.260.26-0.36-0.89-0.61-0.74-0.61-0.75
0.810.730.760.730.380.760.740.62-0.69-0.640.450.730.77-0.330.740.780.23-0.12-0.120.410.690.73-0.740.570.82
0.440.330.70.82-0.10.480.830.89-0.17-0.940.010.250.81-0.360.250.380.35-0.55-0.550.770.390.3-0.610.570.58
0.890.650.890.850.240.950.680.74-0.76-0.760.390.790.7-0.270.350.850.47-0.18-0.180.610.780.92-0.750.820.58
Click cells to compare fundamentals

CytomX Therapeutics Account Relationship Matchups

CytomX Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets341.3M358.7M339.4M260.9M201.8M284.0M
Other Current Liab27.2M19.9M30.6M24.5M17.9M18.0M
Total Current Liabilities85.6M100.9M106.3M152.6M155.9M82.7M
Total Stockholder Equity51.1M49.8M89.4M(85.8M)(47.4M)(45.1M)
Other Liab179.7M186.3M125.7M180.1M207.1M151.2M
Property Plant And Equipment Net32.8M29.4M25.3M21.0M16.2M14.9M
Current Deferred Revenue51.4M74.9M69.3M121.3M132.3M138.9M
Net Debt(163.6M)(167.0M)(187.5M)(175.6M)(3.2M)(3.4M)
Retained Earnings(417.2M)(450.1M)(533.7M)(722.9M)(723.4M)(687.3M)
Accounts Payable4.2M3.0M2.8M2.8M1.5M2.7M
Cash188.4M191.9M205.5M193.7M17.2M16.3M
Non Current Assets Total37.9M34.7M29.1M23.8M18.9M19.5M
Non Currrent Assets Other2.9M(3.4M)(3.7M)(3.6M)1M1.1M
Other Assets2.9M25.6M1.8M944K1.1M1.0M
Cash And Short Term Investments296.1M316.1M305.2M193.7M174.5M253.8M
Net Receivables13K798K790K36.0M3.4M5.6M
Common Stock Shares Outstanding45.3M46.1M64.1M65.7M73.8M48.9M
Short Term Investments188.6M107.7M124.3M99.7M157.3M117.8M
Liabilities And Stockholders Equity341.3M358.7M339.4M260.9M201.8M284.0M
Non Current Liabilities Total204.6M207.9M143.7M194.0M93.3M167.4M
Other Current Assets7.2M14.2M4.3M7.5M5.0M5.9M
Other Stockholder Equity468.3M500.0M623.3M637.1M675.9M709.7M
Total Liab290.2M308.9M250.0M346.6M249.2M250.1M
Property Plant And Equipment Gross32.8M29.4M25.3M21.0M30.9M16.4M
Total Current Assets303.3M324.0M310.3M237.1M182.9M264.6M
Accumulated Other Comprehensive Income57K(47K)(242K)10K95K99.8K
Short Term Debt2.8M3.2M3.6M4.1M9.2M5.3M
Intangible Assets1.3M1.2M1.0M875K729K1.1M
Property Plant Equipment6.9M32.8M7.0M6.0M6.9M8.3M
Net Tangible Assets48.9M47.7M87.4M(2.4M)(2.8M)(2.7M)
Retained Earnings Total Equity(417.2M)(450.1M)(533.7M)(623.6M)(561.2M)(533.1M)
Capital Surpluse446.0M468.3M500.0M623.3M716.8M474.2M
Non Current Liabilities Other850K207.9M143.7M262M3.9M3.7M
Net Invested Capital51.1M49.8M89.4M(85.8M)(47.4M)(45.1M)
Net Working Capital217.7M223.1M204.0M84.5M27.0M25.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.